Want to see STTK full AI Analyst Report?
STTK Stock Chart & Stats
$8.06
$0.34(4.80%)
At close: 4:00 PM EDT
$8.06
$0.34(4.80%)
Day’s Range― - ―
52-Week Range$1.19 - $8.33
Previous CloseN/A
Volume1.47M
Average Volume (3M)869.00K
Market Cap
$693.51M
Enterprise Value$695.04
Total Cash (Recent Filing)$63.30M
Total Debt (Recent Filing)$2.67M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding100,363,250
10 Day Avg. Volume772,680
30 Day Avg. Volume868,996
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.17Price Target Upside88.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$110.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Asset BaseMinimal debt relative to equity gives Shattuck financial flexibility as it funds clinical development. Its sizable asset base provides a buffer, although continued losses could reduce this strength if cash consumption persists.
Promising SL-325 Clinical ProfileDurable target engagement and a favorable early safety profile improve the probability that SL-325 can advance into the planned Phase 2b Crohn’s disease study, creating a clearer clinical development path and potential pipeline value.
Improved Development FundingFresh capital strengthens funding for the inflammatory disease pipeline and may extend development capacity through upcoming trials. Greater liquidity can reduce immediate financing pressure, even though the equity component increases share dilution.
Bears Say
Minimal Revenue And Deep LossesThe company has not established meaningful commercial revenue and remains far from break-even. Negative gross profit and substantial losses mean future progress depends primarily on clinical success and external funding rather than an operating revenue base.
Persistent Cash BurnLarge recurring cash outflows reflect the cost of advancing a clinical-stage pipeline and limit self-funding capacity. Unless spending falls or partnering proceeds increase, Shattuck will likely require additional capital to sustain development.
Ongoing Equity Dilution RiskDependence on equity financing to support operations can materially expand the share base and dilute existing holders. This remains a structural risk while the company lacks product revenue and continues to fund costly clinical programs.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $1.19 and its highest was $8.33 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $693.51M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Nov 10, 2026 which is in 67 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Aug 11, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.004.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.11.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 100,363,250 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went up 0.56%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.17 (88.17% Upside)
$15.17 (88.17% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
443.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
242.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shattuck Labs
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$15.17
▲(88.17% Upside)
Technical Analysis
Neurogene
―
Minerva Neurosciences
―
Anavex Life Sciences
―
Voyager Therapeutics
―
Ovid Therapeutics
―
Ownership Overview
16.35% Insiders
11.05% Mutual Funds
59.47% Other Institutional Investors
5.81% Public Companies and
Individual Investors